CN114246878B - Traditional Chinese medicine extract composition and preparation method and application thereof - Google Patents
Traditional Chinese medicine extract composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN114246878B CN114246878B CN202111625800.9A CN202111625800A CN114246878B CN 114246878 B CN114246878 B CN 114246878B CN 202111625800 A CN202111625800 A CN 202111625800A CN 114246878 B CN114246878 B CN 114246878B
- Authority
- CN
- China
- Prior art keywords
- parts
- acid
- extract
- ethanol
- acteoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims abstract description 67
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 65
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 65
- 229930185474 acteoside Natural products 0.000 claims abstract description 53
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims abstract description 53
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims abstract description 53
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims abstract description 53
- KRZBCHWVBQOTNZ-UHFFFAOYSA-N (-) 3,5-dicaffeoyl-muco-quinic acid Natural products OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-UHFFFAOYSA-N 0.000 claims abstract description 44
- KRZBCHWVBQOTNZ-RDJMKVHDSA-M (-)-3,5-Dicaffeoyl quinic acid Natural products O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C([O-])=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-M 0.000 claims abstract description 44
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 claims abstract description 44
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims abstract description 35
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 34
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940117893 apigenin Drugs 0.000 claims abstract description 34
- 235000008714 apigenin Nutrition 0.000 claims abstract description 34
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims abstract description 34
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 33
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 33
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims abstract description 33
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 33
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 claims abstract description 33
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 claims abstract description 33
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims abstract description 33
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 33
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 33
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 33
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 claims abstract description 33
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 33
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims abstract description 33
- 229960001587 hesperetin Drugs 0.000 claims abstract description 33
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 33
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000008777 kaempferol Nutrition 0.000 claims abstract description 33
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 33
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 33
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 33
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims abstract description 33
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 33
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 33
- 235000005493 rutin Nutrition 0.000 claims abstract description 33
- 229960004555 rutoside Drugs 0.000 claims abstract description 33
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 32
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000005875 quercetin Nutrition 0.000 claims abstract description 32
- 229960001285 quercetin Drugs 0.000 claims abstract description 32
- UFCLZKMFXSILNL-RVXRWRFUSA-N 4,5-di-O-caffeoylquinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-RVXRWRFUSA-N 0.000 claims abstract description 25
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 claims abstract description 15
- 201000007094 prostatitis Diseases 0.000 claims abstract description 14
- 208000019206 urinary tract infection Diseases 0.000 claims abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 96
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 26
- 239000003480 eluent Substances 0.000 claims description 22
- 239000000469 ethanolic extract Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 21
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 claims description 20
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 20
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 claims description 20
- 239000011347 resin Substances 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 19
- 241000628997 Flos Species 0.000 claims description 18
- 238000001179 sorption measurement Methods 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 14
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 13
- 240000008790 Musa x paradisiaca Species 0.000 claims description 13
- 235000015266 Plantago major Nutrition 0.000 claims description 13
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 13
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 13
- 229960004889 salicylic acid Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 230000002485 urinary effect Effects 0.000 claims description 7
- 239000003463 adsorbent Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000012676 herbal extract Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 241000700159 Rattus Species 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 210000002700 urine Anatomy 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 238000000605 extraction Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 206010069918 Bacterial prostatitis Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000722953 Akebia Species 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 241001534096 Psammosilene tunicoides Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241001278833 Rosa laevigata Species 0.000 description 1
- 235000000661 Rosa laevigata Nutrition 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 description 1
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 description 1
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940104299 cimicifugae rhizoma Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmacy, and particularly relates to a traditional Chinese medicine extract composition, and a preparation method and application thereof. The composition comprises the following components: geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin, and oleanolic acid. The preparation method is simple, and can remarkably improve the effect of the composition on treating urinary tract infection and prostatitis.
Description
Technical Field
The invention belongs to the technical field of pharmacy, and particularly relates to a traditional Chinese medicine extract composition, and a preparation method and application thereof.
Background
Urinary tract infections, also known as urinary tract infections, are inflammatory reactions of the urothelium caused by bacterial invasion, usually accompanied by bacterial urine and pustules. Prostatitis (prostatides) refers to a prostate disease that is caused by various complex causes and is mainly clinically manifested by urinary tract irritation symptoms and chronic pelvic pain. Prostatitis is a common disorder of urology surgery and is the leading cause of urology surgery in male patients. Although the incidence of prostatitis is high, its etiology is still not clear, especially non-bacterial prostatitis, and thus its treatment is mainly to improve symptoms.
Related therapeutic products of the prior art are various, and chinese patent application CN102018790a, for example, discloses a composition for treating urinary tract infection. Can control the symptoms of acute urinary tract infection, and has obvious curative effect on persistent urinary tract infection with durable treatment of unhealed antibiotic resistance. The Chinese medicinal composition comprises herba Pteridis Multifidae, herba Commelinae, herba Siraitiae Grosvenorii, herba Hedyotidis Diffusae, herba Polygoni Avicularis, herba Dianthi, cortex Phellodendri and rhizoma Smilacis Glabrae.
The Chinese patent application CN105395866A discloses a traditional Chinese medicine for treating urinary tract infection, which is characterized by being prepared from the following raw materials in percentage by weight: 3-12% of desmodium, 3-15% of pericarpium arecae, 6-10% of psammosilene tunicoides, 3-10% of verbena, 3-10% of stranguria, 3-10% of herba clerodendranthi, 3-10% of cimicifugae rhizoma, 5-10% of akebia stem, 5-20% of fructus polygoni multiflori, 5-15% of herba polygoni multiflori, 10-15% of rush, 10-30% of cherokee rose, 6-10% of rhizoma dioscoreae, 10-30% of polygonum aviculare, 6-10% of glossy privet fruit and 2-10% of cortex lycii radicis, and the raw materials are soaked in water, decocted and deslagged to obtain a filtrate. Soaking the above materials in water, decocting, and removing residues to obtain filtrate. The invention has the effects of clearing heat and detoxicating, excreting dampness and promoting urination, diminishing inflammation and relieving pain, supplementing qi and promoting the production of body fluid, and can dispel wind and reduce fever, promote urination and promote blood circulation, improve the internal and external environment of the organism, thereby treating or relieving various symptoms of urinary tract infection.
However, the therapeutic effect in the prior art still needs to be improved, and meanwhile, part of the raw materials have great side effects due to the interaction among the existing raw materials.
Therefore, the invention aims to provide the composition for treating the urinary tract infection and the prostatitis, which has better effect and less toxic and side effects, and the preparation method is simple, and can obviously improve the effect of the composition on treating the urinary tract infection and the prostatitis.
Disclosure of Invention
In order to overcome the technical problems, the invention provides a traditional Chinese medicine extract composition, which has a simple preparation method and can effectively treat urinary tract infection, improve prostatitis and the like.
In order to achieve the above object, the technical scheme provided by the invention is as follows:
a Chinese medicinal extract composition comprises the following components: geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin, and oleanolic acid.
Preferably, the traditional Chinese medicine extract composition comprises the following components in parts by weight:
1-5 parts of geniposide, 1-10 parts of rutin, 0.1-2 parts of hyperin, 0.1-2 parts of acteoside, 2-10 parts of isochlorogenic acid A, 5-15 parts of isochlorogenic acid C, 0.5-5 parts of quercetin, 1-10 parts of apigenin, 0.1-1 part of kaempferol, 0.1-2 parts of hesperetin and 0.1-1 part of oleanolic acid.
Preferably, the traditional Chinese medicine extract composition comprises the following components in parts by weight:
2-4 parts of geniposide, 5-10 parts of rutin, 0.5-0.8 part of hyperin, 0.5-1 part of acteoside, 5-10 parts of isochlorogenic acid A, 10-15 parts of isochlorogenic acid C, 0.5-2 parts of quercetin, 5-10 parts of apigenin, 0.1-0.5 part of kaempferol, 0.5-1 part of hesperetin and 0.1-0.5 part of oleanolic acid.
Preferably, the traditional Chinese medicine extract composition comprises the following components in parts by weight:
geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The invention also aims at providing a preparation method of the traditional Chinese medicine extract composition, which comprises the following steps: the Chinese medicinal extract composition is prepared by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid or dispersing with solvent.
Preferably, the solvent is ethanol, water or an aqueous ethanol solution.
Preferably, the preparation method of the isochlorogenic acid A comprises the following steps:
(1) Pulverizing flos Lonicerae, extracting with water to obtain water extractive solution and residue;
(2) Extracting the filter residue with ethanol to obtain ethanol extract;
(3) Mixing the ethanol extract and the water extract, extracting with ethyl acetate, separating ethyl acetate phase, adsorbing with macroporous adsorption resin, eluting with ethyl acetate, distilling the eluate under reduced pressure, and drying to obtain flos Lonicerae extract isochlorogenic acid A.
Preferably, in step (1), the temperature of the water extraction is 60-90 ℃.
Preferably, in the step (1), the water is added in an amount which is 8-10 times the mass of the honeysuckle.
Preferably, in the step (2), the ethanol is used in an amount which is 4-6 times the mass of the honeysuckle.
Preferably, in the step (3), in the extraction process, the volume ratio of the ethanol extract and the water extract mixed solution to the ethyl acetate is 1:1-3.
Preferably, in the step (3), the macroporous adsorption resin is AB-8 type and NKA-II type macroporous adsorption resin.
Preferably, the macroporous adsorption resin is adsorbed by AB-8 type and then NKA-II type.
Preferably, in the step (3), the flow rate of the eluent in the ethyl acetate elution process is 0.5-1BV/h.
Preferably, the ethyl acetate is used in an amount of 3-5BV.
Preferably, the preparation method of the acteoside comprises the following steps:
s1, extracting plantain herb with ethanol to obtain an ethanol extract;
s2, adsorbing the ethanol extract by macroporous adsorption resin, eluting by using ethanol water solution, and drying the eluent under reduced pressure to obtain the herba plantaginis extract acteoside.
Preferably, in step S1, the ethanol is 45-75wt% ethanol water solution.
Preferably, in the step S1, salicylic acid is added in the ethanol extraction process, and the use amount of the salicylic acid is 0.1-1% of the mass of the plantain herb.
Preferably, in S2, the concentration of the aqueous ethanol solution is 70-90wt%.
Preferably, in S2, the macroporous adsorbent resin is at least one of HPD100 type and XDA-6 type.
Preferably, in the S2, the flow rate of the eluent is 1-3BV/h in the process of eluting the ethanol water solution.
Preferably, in S2, the ethanol aqueous solution is used in an amount of 1-3BV.
The invention also aims to provide the application of the traditional Chinese medicine extract composition in preparing medicines for treating urinary system infection and prostatitis.
The invention also aims at providing a preparation containing the traditional Chinese medicine extract composition. The preparation comprises any one or more of oral liquid, syrup, capsule, granule and tablet.
Compared with the prior art, the invention has the technical advantages that:
(1) The invention provides a traditional Chinese medicine extract composition, which has better synergistic effect on the treatment of urinary system infection; can be used for treating urinary system infection and prostatitis, and reducing urinary system infection and prostatitis.
(2) In the traditional Chinese medicine extract composition provided by the invention, the isochlorogenic acid A and the isochlorogenic acid C have better synergistic effect, and can effectively clear away heat and toxic materials, and resist bacteria and diminish inflammation. In addition, the invention provides a preparation method of the preferred isochlorogenic acid A, and the isochlorogenic acid A prepared by the method has higher biological activity and has great advantages in the effects of resisting bacteria and diminishing inflammation. Wherein, the combined use of AB-8 type and NKA-II type macroporous adsorption resin can more effectively improve the purification efficiency and activity of isochlorogenic acid A.
(3) The invention provides a preferred scheme of the acteoside, and the addition of salicylic acid in the extraction process can effectively improve the extraction efficiency of the acteoside, and the purity and activity of the acteoside can be effectively improved through the treatment of macroporous adsorption resin.
Detailed Description
The present invention will be described by way of specific examples, to facilitate understanding and grasping of the technical solution of the present invention, but the present invention is not limited thereto. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials, unless otherwise specified, are commercially available.
The components of the compositions used in the examples or comparative examples of the present invention are as follows: geniposide (CAS: 27741-01-1), rutin (CAS: 153-18-4), hyperoside (CAS: 482-36-0), isochlorogenic acid C (CAS: 57378-72-0), quercetin (CAS: 117-39-5), apigenin (CAS: 520-36-5), kaempferol (CAS: 520-18-3), hesperetin (CAS: 520-2), oleanolic acid (CAS: 508-02-1); the purity of the product purchased from the market is more than or equal to 98 percent; the components have no obvious influence on the effect of products of different factories.
The isochlorogenic acid A or the acteoside in the rest examples or the comparative examples are all commercial products and purchased from Nanjing source biological technology Co., ltd, except that the isochlorogenic acid A or the acteoside in the part of examples or the comparative examples is extracted and described, and the purity of the isochlorogenic acid A or the acteoside in the rest examples or the comparative examples is 98%.
Example 1
A Chinese medicinal extract composition comprises the following components: geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Example 2
The traditional Chinese medicine extract composition comprises the following components in parts by weight:
geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the isochlorogenic acid A comprises the following steps:
(1) Pulverizing flos Lonicerae, extracting with 9 times of water at 80deg.C to obtain water extractive solution and residue;
(2) Extracting the residue with 6 times (based on the mass of flos Lonicerae) ethanol to obtain ethanol extractive solution;
(3) Mixing the ethanol extract and the water extract, extracting with ethyl acetate with the volume of 2 times, separating ethyl acetate phase, adsorbing by AB-8 type, adsorbing by NKA-II type, eluting with ethyl acetate, and eluting with the flow rate of 0.5BV/h; the dosage of the ethyl acetate is 5BV; distilling the eluent under reduced pressure, and drying to obtain the flos Lonicerae extract isochlorogenic acid A.
The preparation method of the acteoside comprises the following steps:
s1, extracting plantain herb with 10 times of 60wt% ethanol water solution, wherein salicylic acid is added in the extraction process, and the use amount of the salicylic acid is 0.5% of the mass of the plantain herb to prepare an ethanol extract;
s2, adsorbing the alcohol extract by using HPD100 type macroporous adsorption resin, eluting by using 80wt% of ethanol water solution, and drying the eluent under reduced pressure with the flow rate of the eluent of 1BV/h and the dosage of 3BV to obtain the herba plantaginis extract acteoside.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Example 3
The traditional Chinese medicine extract composition comprises the following components in parts by weight:
5 parts of geniposide, 1 part of rutin, 2 parts of hyperin, 2 parts of acteoside, 10 parts of isochlorogenic acid A, 5 parts of isochlorogenic acid C, 5 parts of quercetin, 10 parts of apigenin, 0.1 part of kaempferol, 2 parts of hesperetin and 1 part of oleanolic acid.
The preparation method of the isochlorogenic acid A comprises the following steps:
(1) Pulverizing flos Lonicerae, extracting with 8 times of water at 90deg.C to obtain water extractive solution and residue;
(2) Extracting the residue with 6 times (based on the mass of flos Lonicerae) ethanol to obtain ethanol extractive solution;
(3) Mixing the ethanol extract and the water extract, extracting by using ethyl acetate with the volume of 1 time, separating an ethyl acetate phase, adsorbing by AB-8 type, adsorbing by NKA-II type, eluting by using ethyl acetate, and eluting with the flow rate of the eluent of 0.5BV/h; the dosage of the ethyl acetate is 3BV; distilling the eluent under reduced pressure, and drying to obtain the flos Lonicerae extract isochlorogenic acid A.
The preparation method of the acteoside comprises the following steps:
s1, extracting plantain herb with 10 times of 45wt% ethanol water solution, wherein salicylic acid is added in the extraction process, and the use amount of the salicylic acid is 0.1% of the mass of the plantain herb to prepare an ethanol extract;
s2, adsorbing the alcohol extract by using XDA-6 macroporous adsorption resin, eluting by using 70wt% ethanol water solution, wherein the flow rate of the eluent is 3BV/h, and the use amount of the eluent is 1BV, and drying under reduced pressure to obtain the herba plantaginis extract acteoside.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Example 4
The traditional Chinese medicine extract composition comprises the following components in parts by weight:
1 part of geniposide, 10 parts of rutin, 0.1 part of hyperin, 0.1 part of acteoside, 2 parts of isochlorogenic acid A, 15 parts of isochlorogenic acid C, 0.5 part of quercetin, 1 part of apigenin, 1 part of kaempferol, 0.1 part of hesperetin and 0.1 part of oleanolic acid.
The preparation method of the isochlorogenic acid A comprises the following steps:
(1) Pulverizing flos Lonicerae, extracting with 10 times of water at 60deg.C to obtain water extractive solution and residue;
(2) Extracting the filter residue with 4 times (based on the mass of the honeysuckle) of ethanol to obtain an ethanol extract;
(3) Mixing the ethanol extract and the water extract, extracting by using ethyl acetate with the volume of 3 times, separating an ethyl acetate phase, adsorbing by AB-8 type, adsorbing by NKA-II type, eluting by using ethyl acetate, and eluting with the flow rate of the eluent of 1BV/h; the dosage of the ethyl acetate is 5BV; distilling the eluent under reduced pressure, and drying to obtain the flos Lonicerae extract isochlorogenic acid A.
The preparation method of the acteoside comprises the following steps:
s1, extracting plantain herb with 10 times of 75wt% ethanol water solution, wherein salicylic acid is added in the extraction process, and the use amount of the salicylic acid is 1% of the mass of the plantain herb to prepare an ethanol extract;
s2, adsorbing the alcohol extract by using HPD100 type macroporous adsorption resin, eluting by using 90wt% of ethanol water solution, and drying the eluent under reduced pressure with the flow rate of the eluent of 1BV/h and the dosage of 3BV to obtain the herba plantaginis extract acteoside.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Example 5
The traditional Chinese medicine extract composition comprises the following components in parts by weight:
geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the isochlorogenic acid A comprises the following steps:
(1) Pulverizing flos Lonicerae, extracting with 9 times of water at 80deg.C to obtain water extractive solution and residue;
(2) Extracting the residue with 6 times (based on the mass of flos Lonicerae) ethanol to obtain ethanol extractive solution;
(3) Mixing the ethanol extract and the water extract, extracting with ethyl acetate with the volume of 2 times, separating ethyl acetate phase, adsorbing by AB-8 type, adsorbing by NKA-II type, eluting with ethyl acetate, and eluting with the flow rate of 0.5BV/h; the dosage of the ethyl acetate is 5BV; distilling the eluent under reduced pressure, and drying to obtain the flos Lonicerae extract isochlorogenic acid A.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside (commercial product), isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Example 6
The traditional Chinese medicine extract composition comprises the following components in parts by weight:
geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the acteoside comprises the following steps:
s1, extracting plantain herb with 10 times of 60wt% ethanol water solution, wherein salicylic acid is added in the extraction process, and the use amount of the salicylic acid is 0.5% of the mass of the plantain herb to prepare an ethanol extract;
s2, adsorbing the alcohol extract by using HPD100 type macroporous adsorption resin, eluting by using 80wt% of ethanol water solution, and drying the eluent under reduced pressure with the flow rate of the eluent of 1BV/h and the dosage of 3BV to obtain the herba plantaginis extract acteoside.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A (commercial product is used), isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Example 7
In comparison with example 5, the difference is that the method for producing isochlorogenic acid A is different.
The traditional Chinese medicine extract composition comprises the following components in parts by weight:
geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the isochlorogenic acid A comprises the following steps:
(1) Pulverizing flos Lonicerae, extracting with 9 times of water at 80deg.C to obtain water extractive solution and residue;
(2) Extracting the residue with 6 times (based on the mass of flos Lonicerae) ethanol to obtain ethanol extractive solution;
(3) Mixing the ethanol extract and the water extract, extracting with ethyl acetate with the volume of 2 times, separating ethyl acetate phase, adsorbing twice by AB-8 type, eluting with ethyl acetate, and eluting with the flow rate of 0.5BV/h; the dosage of the ethyl acetate is 5BV; distilling the eluent under reduced pressure, and drying to obtain the flos Lonicerae extract isochlorogenic acid A.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Example 8
The difference compared to example 6 is the preparation of acteoside.
The traditional Chinese medicine extract composition comprises the following components in parts by weight:
geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the acteoside comprises the following steps:
s1, taking plantain, adding 10 times of 60wt% of ethanol aqueous solution for extraction to prepare ethanol extract;
s2, adsorbing the alcohol extract by using HPD100 type macroporous adsorption resin, eluting by using 80wt% of ethanol water solution, and drying the eluent under reduced pressure with the flow rate of the eluent of 1BV/h and the dosage of 3BV to obtain the herba plantaginis extract acteoside.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Comparative example 1
The difference from example 1 is that acteoside is used instead of hyperoside, unlike the composition.
A Chinese medicinal extract composition comprises the following components: geniposide 3.38 parts, rutin 5.93 parts, acteoside 1.56 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the traditional Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Comparative example 2
The difference from example 1 is that instead of the acteoside, hyperin was used as a component.
A Chinese medicinal extract composition comprises the following components: geniposide 3.38 parts, rutin 5.93 parts, hyperin 1.56 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the traditional Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperin, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid.
Comparative example 3
The difference from example 1 is that apigenin is used instead of quercetin, unlike the composition.
A Chinese medicinal extract composition comprises the following components: 3.38 parts of geniposide, 5.93 parts of rutin, 0.77 part of hyperin, 0.79 part of acteoside, 8.63 parts of isochlorogenic acid A, 13.75 parts of isochlorogenic acid C, 6.14 parts of apigenin, 0.2 part of kaempferol, 0.63 part of hesperetin and 0.35 part of oleanolic acid.
The preparation method of the traditional Chinese medicine extract composition comprises the following steps: the traditional Chinese medicine extract composition is obtained by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, apigenin, kaempferol, hesperetin and oleanolic acid.
Effect test
The Chinese medicinal extract compositions of examples 1-8 and comparative examples 1-3 were mixed with magnesium stearate as excipient to prepare powder, and the powder contained 20g/g of excipient. When in use, the powder is dispersed with distilled water with equal amount, and is uniformly shaken when in use, and is preserved at 4 ℃. The Chinese medicinal extract compositions of examples 1 to 8 and comparative examples 1 to 3 were evaluated for their therapeutic activities on urinary system infection diseases and prostatitis.
Dose selection: according to the effective components, the high dose is 200mg/kg, the medium dose is 100mg/kg, and the low dose is 50mg/kg; during the test, example 1 was administered in high, medium and low dose groups, and examples 2-8 and comparative examples 1-3 were all administered in low doses (50 mg/kg).
1. Test animals
(1) SPF-class Wistar rats, weighing 200-220 g, are used between male and female. The production license SCXK 2007-0003, the use license SYXK 2007-0011 is provided by the institute of medicine and infrastructure laboratory animal center at Jilin university. Rat rearing room, temperature: 23+ -1deg.C, humidity: 50-70%, and illumination: 150-200Lx,12 hours of alternating light and shade (6:00 early-18:00 late); noise: < 50dB; an environment automatic control system is arranged.
2. Feeding conditions
(1) And (3) drinking water: tap water is filtered and sterilized, and is placed in an autoclave for drinking.
(2) Common feed (basal feed): complete nutrition granulated feed for mice, co 60 And (5) radiation sterilization.
(3) The feeding mode is as follows: free diet, sufficient water and feed were given to the cages, 8 rats were fed per cage, randomly grouped before adaptation, and each weighing and feeding condition recorded once during and before adaptation. During the whole experimental period, rats were kept under the 3R principle used by the experimental animals during the experimental feeding and experimental operation, giving humane care.
3. Positive control drug selection
(1) Levofloxacin tablets, which are ground at the time of use, are selected from 25mg/kg of rats, produced by Chengdu Hengrui pharmaceutical Co., ltd., lot number: 200606.
(2) The Qianlietong tablet is sugar-coated tablet, the sugar-coated tablet is light brown to brown after sugar coating is removed, the weight of a substrate is 0.34g, the dosage of a selected rat is 2.75g/kg, which is equivalent to 5 times of equivalent dosage, sugar coating is removed when the tablet is used, the tablet is ground, distilled water is used for preparing the required concentration, animals are all subjected to gastric administration, and the tablet is produced by pharmaceutical industry Co., ltd in white cloud mountain, guangzhou, batch number: 20200604.
4. data statistics method
Statistical analysis was performed using SPSS 16.0, where the metrology data meeting normal distribution was tested using analysis of variance to
A representation; the grade data and the measurement data which do not accord with normal distribution are represented by Mean Ranks by adopting a non-parameter test method. The difference of P < 0.05 is statistically significant.
5. Rat urinary tract infection test by escherichia coli
Rats were individually placed in metabolic cages (the cages were sterilized) prior to infection, urine volume was measured for 10 hours and recorded, while urine samples were withdrawn (less than 10ml urine volume, rats continued to retain urine). The number of white blood cells is measured by a urine precipitation method, and the bacterial content in urine is measured by a quantitative inoculation method.
The rats were pre-dehydrated for 24 hours at the time of the experiment, and under ether anesthesia, the E.coli ATCC44102 strain solution (10 5 Per ml) of the strain is 0.5 ml/piece, then the abdominal cavity is closed, the penis of the rat is tightly tied by a silk thread before the strain is injected, so that the strain is prevented from leaking out, and the penis tying wire is loosened after 1 h. After all model rats are revived, carefully feeding, observing for 7 days, measuring urine volume of each rat for 10 hours after infection on the 8 th day, and taking more than 10 ten thousand bacteria in urine and white blood cell number in urine per ml as infected qualified rats, removing unqualified rats, wherein the qualified rats are randomly divided into:
example 1 compositions high, medium, low dose groups, examples 2-8 and comparative examples 1-3, positive drug levofloxacin and model control; 10 rats per group; each group of animals is respectively irrigated with the drug solution of the corresponding group, and 10 normal rats which are not infected are taken as the normal control group; the model control group and the normal control group are given with equal volume of excipient according to high dosage, are given once daily after being grouped, and are continuously given by gastric lavage for 7 days. The urine volume, bacterial count in urine and leukocyte count in urinary sediment/. Times.400 at 5 hours after the last administration were measured 10 hours after 7 days of withdrawal according to the above method, and the results are shown in Table 1.
The results show that the composition provided by the invention has different degrees of reducing effects on the urinary tract infection of rats, the white blood cell count in urine and the bacterial content in urine caused by escherichia coli, and can increase the urine volume for 10 hours. The high and medium dose effects are most obvious, and the high and medium dose effects are statistically processed by self comparison or comparison with a control. The product has good effects of diminishing inflammation, inhibiting bacteria and promoting urination.
6. Test results of bacterial prostatitis in rats caused by Escherichia coli
Modeling of inflammatory: the rats were randomly divided into a blank control group, a model control group, and high, medium and low dose groups of example 1, examples 2 to 8, comparative examples 1 to 3, positive drug groups (Qianlietong tablets), 10 rats per group; after 1 week of domestication, 10% chloral hydrate (3.5 mL/kg) was injected into abdominal cavity for anesthesia, after the skin of the abdomen of the rat was disinfected with 75% alcohol, 1 incision of about 0.5-1cm was made in the middle of the lower abdomen of the rat, the abdominal wall and peritoneum were cut, the prostate was exposed, and 1.5X10 each of the two sides of the dorsal lobe of the prostate was injected 7 cfu/mL concentration of Escherichia coli 0.1mL, rats in the blank group were injected with the same amount of 0.9% sodium chloride solution at the same position by the same method, the prostate was reset after injection, abdominal wall muscles and skin were sutured layer by layer, and the rats were returned to the squirrel cage for free diet.
Wherein, the animals in the high, medium and low dose groups of the example 1, the examples 2-8, the comparative examples 1-3 and the positive medicine groups begin to be administrated by group and dose group by group and stomach infusion 5 days before the animals are inflammatory; model and placebo groups were given equal volumes of vehicle at high doses. Continuously administering for 3 days after inflammatory for 1 time every day, killing rats after end-breaking 1 hour after last administration, taking 100mg of prostate under aseptic condition, fully mixing in 1ml of physiological saline, and recording the white blood cell number and the lecithin body number under a lens; meanwhile, the prostate liquid is inoculated on a common blood agar plate and cultured for 48 hours at 37 ℃. The colony count was recorded and the results are shown in Table 2.
After 1 week of operation molding, 3 blank control groups are randomly extracted, 3 model control groups are randomly extracted, the prostate is stripped after anesthesia, pathological sections and HE staining are manufactured after fixation by 10% formaldehyde solution, and the model is verified to be successful.
TABLE 2 Effect of prostate fluid test index in a rat bacterial prostatitis model
Note that: in the same column, the different letters represent a significant difference P < 0.05.
The results show that the high and medium dose groups of the composition have obvious effects of reducing the number of white blood cells and improving the density of the lecithin bodies on a bacterial prostatitis model of a rat caused by escherichia coli, and can also reduce the number of bacteria in the prostate of the rat with prostatitis, and have statistical significance compared with a model control group.
The foregoing detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but is to be accorded the full scope of all such equivalents and modifications so as not to depart from the scope of the invention.
Claims (12)
1. A traditional Chinese medicine extract composition for treating urinary system infection or prostatitis is characterized by comprising the following components in parts by weight: 1-5 parts of geniposide, 1-10 parts of rutin, 0.1-2 parts of hyperin, 0.1-2 parts of acteoside, 2-10 parts of isochlorogenic acid A, 5-15 parts of isochlorogenic acid C, 0.5-5 parts of quercetin, 1-10 parts of apigenin, 0.1-1 part of kaempferol, 0.1-2 parts of hesperetin and 0.1-1 part of oleanolic acid.
2. The traditional Chinese medicine extract composition according to claim 1, which comprises the following components in parts by weight: 2-4 parts of geniposide, 5-10 parts of rutin, 0.5-0.8 part of hyperin, 0.5-1 part of acteoside, 5-10 parts of isochlorogenic acid A, 10-15 parts of isochlorogenic acid C, 0.5-2 parts of quercetin, 5-10 parts of apigenin, 0.1-0.5 part of kaempferol, 0.5-1 part of hesperetin and 0.1-0.5 part of oleanolic acid.
3. The traditional Chinese medicine extract composition according to claim 1, which comprises the following components in parts by weight: geniposide 3.38 parts, rutin 5.93 parts, hyperin 0.77 parts, acteoside 0.79 parts, isochlorogenic acid A8.63 parts, isochlorogenic acid C13.75 parts, quercetin 1.0 parts, apigenin 5.14 parts, kaempferol 0.2 parts, hesperetin 0.63 parts, and oleanolic acid 0.35 parts.
4. The traditional Chinese medicine extract composition according to claim 1, wherein the preparation method of the isochlorogenic acid A comprises the following steps:
(1) Pulverizing flos Lonicerae, extracting with water to obtain water extractive solution and residue;
(2) Extracting the filter residue with ethanol to obtain ethanol extract;
(3) Mixing the ethanol extract and the water extract, extracting with ethyl acetate, separating ethyl acetate phase, adsorbing with macroporous adsorption resin, eluting with ethyl acetate, distilling the eluate under reduced pressure, and drying to obtain flos Lonicerae extract isochlorogenic acid A.
5. The composition of claim 4, wherein in step (3), the ratio of the volume of the mixture of the ethanol extract and the water extract to the volume of the ethyl acetate is 1:1-3.
6. The composition of claim 4, wherein in step (3), the macroporous adsorbent resin is an AB-8 type and NKA-ii type macroporous adsorbent resin; the macroporous adsorption resin is adsorbed by AB-8 type and then NKA-II type.
7. The composition of claim 4, wherein in step (3), the flow rate of the eluent is 0.5-1BV/h during the elution with ethyl acetate; the dosage of the ethyl acetate is 3-5BV.
8. The traditional Chinese medicine extract composition according to any one of claims 1 to 7, wherein the preparation method of the acteoside comprises the following steps:
s1, extracting plantain herb with ethanol to obtain an ethanol extract;
s2, adsorbing the ethanol extract by macroporous adsorption resin, eluting by using ethanol water solution, and drying the eluent under reduced pressure to obtain the herba plantaginis extract acteoside.
9. The Chinese medicinal extract composition according to claim 8, wherein in step S1, salicylic acid is added during the ethanol extraction, and the amount of salicylic acid is 0.1-1% of the mass of plantain herb; in S2, the macroporous adsorption resin is at least one of HPD100 type and XDA-6 type.
10. The method for preparing a Chinese medicinal extract composition according to any one of claims 1 to 9, comprising the steps of: the Chinese medicinal extract composition is prepared by directly mixing geniposide, rutin, hyperoside, acteoside, isochlorogenic acid A, isochlorogenic acid C, quercetin, apigenin, kaempferol, hesperetin and oleanolic acid or dispersing with solvent.
11. The use of a composition of matter according to any one of claims 1 to 9, in the preparation of a medicament for the treatment of urinary tract infections or prostatitis.
12. A formulation comprising the herbal extract composition of any one of claims 1-9, wherein the formulation is selected from any one or more of an oral liquid, a syrup, a capsule, a granule, and a tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111625800.9A CN114246878B (en) | 2021-12-28 | 2021-12-28 | Traditional Chinese medicine extract composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111625800.9A CN114246878B (en) | 2021-12-28 | 2021-12-28 | Traditional Chinese medicine extract composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114246878A CN114246878A (en) | 2022-03-29 |
| CN114246878B true CN114246878B (en) | 2023-04-28 |
Family
ID=80798523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111625800.9A Active CN114246878B (en) | 2021-12-28 | 2021-12-28 | Traditional Chinese medicine extract composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114246878B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154481B (en) * | 2022-09-07 | 2022-11-11 | 吉林华康药业股份有限公司 | A Chinese medicinal composition for preventing and treating atherosclerosis and coronary heart disease |
| CN115607638B (en) * | 2022-12-02 | 2023-03-21 | 吉林华康药业股份有限公司 | Traditional Chinese medicine composition for treating infantile indigestion with food retention and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012214500A (en) * | 2012-08-03 | 2012-11-08 | Jianxun Liu | Chinese medicine compositions and their preparation process and use |
| CN110538189A (en) * | 2019-09-22 | 2019-12-06 | 江西普正制药股份有限公司 | Eucommia ulmoides extract composition for treating renal fibrosis and application thereof |
| CN113350386A (en) * | 2021-07-07 | 2021-09-07 | 江西普正制药股份有限公司 | Composition containing pinoresinol diglucoside and genipin and application thereof |
| CN113413392A (en) * | 2021-07-07 | 2021-09-21 | 江西普正制药股份有限公司 | Eucommia ulmoides extract composition and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600219B (en) * | 2012-03-21 | 2013-02-13 | 江苏苏中药业集团股份有限公司 | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract |
| EP3251683A4 (en) * | 2015-01-30 | 2018-09-26 | Sichuan Jiuzhang Biological Science And Technology Co., Ltd | Eucommia leaf extract, and preparation method and use thereof |
-
2021
- 2021-12-28 CN CN202111625800.9A patent/CN114246878B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012214500A (en) * | 2012-08-03 | 2012-11-08 | Jianxun Liu | Chinese medicine compositions and their preparation process and use |
| CN110538189A (en) * | 2019-09-22 | 2019-12-06 | 江西普正制药股份有限公司 | Eucommia ulmoides extract composition for treating renal fibrosis and application thereof |
| CN113350386A (en) * | 2021-07-07 | 2021-09-07 | 江西普正制药股份有限公司 | Composition containing pinoresinol diglucoside and genipin and application thereof |
| CN113413392A (en) * | 2021-07-07 | 2021-09-21 | 江西普正制药股份有限公司 | Eucommia ulmoides extract composition and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Kalina Alipieva等.Verbascoside--a review of its occurrence, (bio)synthesis and pharmacological significance.Biotechnol Adv.2014,第1卷(第32期),1065-1076. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114246878A (en) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102698123B (en) | Traditional Chinese medicinal composition for treating transmissible gastroenteritis of swine, feed, preparation method and application thereof | |
| CN114246878B (en) | Traditional Chinese medicine extract composition and preparation method and application thereof | |
| CN101744924B (en) | Multiple-effect Chinese herbal medicine compound of bacterial diseases of turbot | |
| CN103800634B (en) | Chinese herbal medicine feed additive for controlling main bacterial infectious diseases of freshwater fish | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN101972391A (en) | Medicinal composition used for treating swine mastitis and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN102793869B (en) | Traditional Chinese medicine composition for controlling porcine viral diseases and preparation method thereof | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN105250727A (en) | Traditional Chinese medicine composition for prevention and treatment of livestock diarrhea and preparation method of traditional Chinese medicine composition | |
| CN101085048B (en) | Traditional Chinese medicine for detoxicating for animals and preparation method thereof | |
| CN111544570B (en) | Antiviral preparation added with antibacterial peptide and preparation method thereof | |
| CN112023018B (en) | Traditional Chinese medicine composition for preventing and treating livestock diarrhea and preparation method and application thereof | |
| CN103479786B (en) | Traditional Chinese medicine composition for treating PRRS (Porcine Reproductive and Respiratory Syndrome) and preparation method and application thereof | |
| CN111346172B (en) | Pharmaceutical composition for improving immunity | |
| CN103479789B (en) | Traditional Chinese medicine composition for treating PRRS (Porcine Reproductive and Respiratory Syndrome) and preparation method and application thereof | |
| CN113813306B (en) | Traditional Chinese medicine composition for preventing and treating infectious rhinitis of chicken | |
| CN109091646B (en) | Compound traditional Chinese medicine preparation for miscarriage prevention of livestock and preparation method thereof | |
| TWI740228B (en) | Chinese herbal medicine composition for livestock | |
| CN100372546C (en) | Chinese medicinal preparation for treating prostatitis and its preparation method | |
| CN101554397B (en) | Applications of eucommia ulmoide total alkaloid | |
| CN109771480B (en) | Traditional Chinese medicine composition for treating livestock and poultry hepatotoxicity and preparation method and preparation thereof | |
| CN117679477A (en) | Traditional Chinese medicine composition for treating qi and yin deficiency syndrome after malignant tumor radiotherapy | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method | |
| CN105535429A (en) | Traditional Chinese medicine for treating Parkinson's disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |